[go: up one dir, main page]

AU1091200A - Method of treating prostate cancer with an adenovirus vector - Google Patents

Method of treating prostate cancer with an adenovirus vector

Info

Publication number
AU1091200A
AU1091200A AU10912/00A AU1091200A AU1091200A AU 1091200 A AU1091200 A AU 1091200A AU 10912/00 A AU10912/00 A AU 10912/00A AU 1091200 A AU1091200 A AU 1091200A AU 1091200 A AU1091200 A AU 1091200A
Authority
AU
Australia
Prior art keywords
prostate cancer
adenovirus vector
treating prostate
treating
adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10912/00A
Inventor
Mitchell S. Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENOTHERAPEUTICS Inc
Original Assignee
GENOTHERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GENOTHERAPEUTICS Inc filed Critical GENOTHERAPEUTICS Inc
Publication of AU1091200A publication Critical patent/AU1091200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU10912/00A 1998-10-02 1999-10-01 Method of treating prostate cancer with an adenovirus vector Abandoned AU1091200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16573098A 1998-10-02 1998-10-02
US09165730 1998-10-02
PCT/US1999/020907 WO2000020038A1 (en) 1998-10-02 1999-10-01 Method of treating prostate cancer with an adenovirus vector

Publications (1)

Publication Number Publication Date
AU1091200A true AU1091200A (en) 2000-04-26

Family

ID=22600207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10912/00A Abandoned AU1091200A (en) 1998-10-02 1999-10-01 Method of treating prostate cancer with an adenovirus vector

Country Status (2)

Country Link
AU (1) AU1091200A (en)
WO (1) WO2000020038A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101261869B1 (en) 2006-03-28 2013-05-07 동아쏘시오홀딩스 주식회사 A gene delivering vector comprising the gene encoding soluble and secretable homotrimer forming recombinant human TRAIL

Also Published As

Publication number Publication date
WO2000020038A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
AU1527897A (en) Method for treating the prostate
AU6949498A (en) Method for assessing prostate cancer
AU1939200A (en) Electrochemical treatment of malignant tumors
AU6688598A (en) Method for diagnosing and staging prostate cancer
HUP0000261A3 (en) Means for treating prostate hypertrophy and prostate cancer
AU6136999A (en) Method and system for improved detection of prostate cancer
EP1176964B8 (en) Uses of et743 for treating cancer
HUP0104857A3 (en) New cancer treatments
AU4823599A (en) Prostate cancer-associated genes
AU6249098A (en) Method of treating cancer using alkylglycerols in conjunction with chemotherapy
AU2238499A (en) Androgen-metabolic gene mutations and prostate cancer risk
AU9689398A (en) Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
AU9018598A (en) Prognostic compositions for prostate cancer and methods of use thereof
AU2506499A (en) Cea/nca-based differentiation cancer therapy
AU1091200A (en) Method of treating prostate cancer with an adenovirus vector
AU2342299A (en) Compositions and methods for detecting and treating breast cancer
AU6387499A (en) Method of treating prostate cancer with an adenovirus expression vector encodinga prodrug enzyme
AU5369498A (en) Compounds and methods for treating cancer
AU7936898A (en) Vectors for treating cancer
AU5316099A (en) Prostate cancer assays and related methods
AU4417996A (en) Treatment of prostate cancer
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
AU5097099A (en) Methods and compositions for cancer treatment
AUPO851597A0 (en) Treatment of prostate cancer
AU1669600A (en) New cancer treatments

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase